Publication:
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.

dc.contributor.authorGarcía-Alonso, Sara
dc.contributor.authorMesa, Pablo
dc.contributor.authorOvejero, Laura de la Puente
dc.contributor.authorAizpurua, Gonzalo
dc.contributor.authorLechuga, Carmen G
dc.contributor.authorZarzuela, Eduardo
dc.contributor.authorSantiveri, Clara M
dc.contributor.authorSanclemente, Manuel
dc.contributor.authorMuñoz, Javier
dc.contributor.authorMusteanu, Mónica
dc.contributor.authorCampos-Olivas, Ramón
dc.contributor.authorMartínez-Torrecuadrada, Jorge
dc.contributor.authorBarbacid, Mariano
dc.contributor.authorMontoya, Guillermo
dc.contributor.funderEuropean Research Council (ERC)
dc.contributor.funderAsociación Española contra el Cáncer
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderCRIS Cancer Foundation
dc.contributor.funderComunidad de Madrid (Esapña)
dc.contributor.funderNovo Nordisk Foundation
dc.date.accessioned2025-07-01T10:11:23Z
dc.date.available2025-07-01T10:11:23Z
dc.date.issued2022-09-15
dc.descriptionWe thank the Danish Cryo-EM National Facility in CFIM at the University of Co-penhagen for support during cryo-EM data collection. We also thank the Pro-tein Expression Unit at CPR for assistance in protein expression and purification. S.G.-A. is a recipient of a postdoctoral fellowship from the Spanish Association against Cancer Scientific Foundation (FCAECC) . This work was supported by grants from the European Research Council (ERC-2015-AdG/695566, THERACAN) , the Spanish Ministry of Science, Innovation and Universities (RTC-2017-6576-1) , the Autonomous Community of Madrid (B2017/BMD-3884 iLUNG-CM) , the CRIS Cancer Foundation, and the AECC (GC16173694BARB) to M.B. and by a grant from the Spanish Ministry of Science, Innovation and Universities (RTI2018-094664-B-I00) to M.B. and M.M.; M.B. is a recipient of an Endowed Chair from the AXA Research Fund. The Experimental Oncology group is a member of CIBERONC. G.M. is part of the Novo Nordisk Foundation Center for Protein Research (CPR) , which is sup-ported financially by the Novo Nordisk Foundation (grant NNF14CC0001) . This work was also supported by grant NNF0024386, grant NNF17SA0030214, and Distinguished Investigator grant NNF18OC0055061 to G.M., who is a member of the Integrative Structural Biology Cluster (ISBUC) at the University of Copenhagen
dc.description.abstractRAF kinases are RAS-activated enzymes that initiate signaling through the MAPK cascade to control cellular proliferation, differentiation, and survival. Here, we describe the structure of the full-length RAF1 protein in complex with HSP90 and CDC37 obtained by cryoelectron microscopy. The reconstruction reveals a RAF1 kinase with an unfolded N-lobe separated from its C-lobe. The hydrophobic core of the N-lobe is trapped in the HSP90 dimer, while CDC37 wraps around the chaperone and interacts with the N- and C-lobes of the kinase. The structure indicates how CDC37 can discriminate between the different members of the RAF family. Our structural analysis also reveals that the folded RAF1 assembles with 14-3-3 dimers, suggesting that after folding RAF1 follows a similar activation as B-RAF. Finally, disruption of the interaction between CDC37 and the DFG segment of RAF1 unveils potential vulnerabilities in attempting the pharmacological degradation of RAF1 for therapeutic purposes.
dc.description.peerreviewed
dc.format.number18
dc.format.page3438-3452
dc.format.volume82
dc.identifier.citationMol Cell . 2022 Sep 15;82(18):3438-3452
dc.identifier.journalMolecular Cell
dc.identifier.pubmedID36055235
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26791
dc.language.isoeng
dc.publisherCell Press
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-094664-B-I00/ES/C-RAF, UN MEDIADOR CLAVE EN TUMORES INDUCIDOS POR EL ONCOGEN K-RAS: ESTRATEGIAS TERAPEUTICAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/695566/EU
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/RTC-2017-6576-1/ES/NUEVOS ABORDAJES EN EL TRATAMIENTO DE CANCER DE PULMON/
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-094664-B-I00/ES/C-RAF, UN MEDIADOR CLAVE EN TUMORES INDUCIDOS POR EL ONCOGEN K-RAS: ESTRATEGIAS TERAPEUTICAS/
dc.relation.publisherversionhttps://doi: 10.1016/j.molcel.2022.08.012
dc.repisalud.institucionCNIO
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Oncología Experimental
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectMAPK signaling
dc.subjectRAF kinases
dc.subjectRAF1
dc.subjectcancer
dc.subjectcryo-EM
dc.titleStructure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationaff72b01-c3b6-455f-b4d5-abd12819cadb
relation.isAuthorOfPublication728b1f96-276b-4ab5-8640-8964fb72939f
relation.isAuthorOfPublication.latestForDiscovery728b1f96-276b-4ab5-8640-8964fb72939f

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
structureoftheraf-2022.pdf
Size:
6.98 MB
Format:
Adobe Portable Document Format